1639P Integrated safety analysis of tazemetostat (TAZ) 800 mg BID in adult patients (pts) with hematologic and solid tumors

MLA

George D. Demetri, et al. “1639P Integrated Safety Analysis of Tazemetostat (TAZ) 800 Mg BID in Adult Patients (Pts) with Hematologic and Solid Tumors.” Annals of Oncology, vol. 31, Sept. 2020, pp. S981–82. EBSCOhost, https://doi.org/10.1016/j.annonc.2020.08.1865.

APA

George D. Demetri, Marjorie G. Zauderer, Mrinal M. Gounder, Hervé Tilly, P. Slatcher, Dean A. Fennell, Victor M. Villalobos, Jay Yang, Gregory M. Cote, Gilles Salles, Aristeidis Chaidos, L. Sierra, Patrick Schöffski, Shefali Agarwal, Robin L. Jones, Tycel Phillips, Franck Morschhauser, Gary K. Schwartz, Pamela McKay, & Silvia Stacchiotti. (2020). 1639P Integrated safety analysis of tazemetostat (TAZ) 800 mg BID in adult patients (pts) with hematologic and solid tumors. Annals of Oncology, 31, S981–S982. https://doi.org/10.1016/j.annonc.2020.08.1865

Chicago

George D. Demetri, Marjorie G. Zauderer, Mrinal M. Gounder, Hervé Tilly, P. Slatcher, Dean A. Fennell, Victor M. Villalobos, et al. 2020. “1639P Integrated Safety Analysis of Tazemetostat (TAZ) 800 Mg BID in Adult Patients (Pts) with Hematologic and Solid Tumors.” Annals of Oncology 31 (September): S981–82. doi:10.1016/j.annonc.2020.08.1865.